Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,099.00+2.92%ETH$2,419.99+5.48%GOLD$4,075.60+3.43%OIL$88.49-7.91%
Smart Investors Daily
SID Premium
GA

NASDAQ · GANX

Gain Therapeutics, Inc.

Healthcare · Biotechnology

$1.15

Down-$0.04 (-3.48%)

Updated Nov 4, 2026, 9:22 PM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
148.53M
P/E ratio
-6.72
Dividend yield
0.00%
52-week range
$1.11 – $3.07
Volume
193.74K
Avg. volume
1.01M

Price performance · GANX

GANX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

GANX closed at $1.15 after 21 trading sessions, down 31.14% for the selected period.

Last close
$1.15
Period change
-31.14%
Period low
$1.13
Period high
$1.67
Daily close
View OHLC price history
GANX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.13$1.19$1.13$1.15193.74K
Nov 2, 2026$1.15$1.20$1.12$1.13268.67K
Oct 30, 2026$1.18$1.195$1.11$1.13364.65K
Oct 29, 2026$1.20$1.25$1.17$1.19177.2K
Oct 28, 2026$1.16$1.20$1.16$1.195400.43K
Oct 27, 2026$1.16$1.21$1.14$1.17508.34K
Oct 26, 2026$1.28$1.28$1.14$1.15811.02K
Oct 23, 2026$1.33$1.3432$1.22$1.26645.03K
Oct 22, 2026$1.18$1.33$1.16$1.292.75M
Oct 21, 2026$1.20$1.23$1.15$1.19609.77K
Oct 20, 2026$1.23$1.295$1.17$1.19517K
Oct 19, 2026$1.26$1.2899$1.21$1.25532.17K
Oct 16, 2026$1.32$1.377$1.235$1.26467.38K
Oct 15, 2026$1.32$1.41$1.31$1.33510.82K
Oct 14, 2026$1.37$1.42$1.295$1.32851.3K
Oct 13, 2026$1.58$1.58$1.40$1.41800.29K
Oct 12, 2026$1.65$1.65$1.565$1.57319.8K
Oct 9, 2026$1.61$1.66$1.6099$1.64328.69K
Oct 8, 2026$1.66$1.675$1.61$1.615361.86K
Oct 7, 2026$1.66$1.69$1.64$1.67373.93K
Oct 6, 2026$1.70$1.75$1.655$1.67646.56K

Latest GANX news

The latest Smart Investors Daily articles mentioning GANX.

Stock researchCompany · Overview

GANX research

Overview

Company profile and research snapshot.

Company profile

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.50
Implied upside
—
Analysts
11
GANX recent ratings
DateFirmRatingTarget
Oct 5, 2026HC Wainwright & Co.Buy—
Aug 31, 2026HC Wainwright & Co.Buy—
Aug 11, 2026BTIGBuy—
Jul 1, 2026HC Wainwright & Co.Buy—
Jun 30, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

Gain Therapeutics to Attend the 2026 Maxim Growth Summit

BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small-molecule therapies, today announced it will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel New York, in New York City. Gain Therapeutics will be meeting with institutional investors in one-on-one

Yahoo · Oct 1, 2026

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026 Participants with both high and low baseline levels of GluSph experienced stabilization of MDS-UPDRS motor scores by 12 months Results support disease-modifying potential of rexaceract along with a favorable tolerability profile; no significant safety signals observed

Benzinga · Oct 1, 2026

Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of Rexaceract

Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By